Newsroom

HOUSTON--(BUSINESS WIRE)--HPE (NYSE: HPE) will conduct a live audio webcast of a conference call with analysts to review financial results for the third quarter of fiscal 2026, ending July 31, 2026. The call is scheduled for Wednesday, September 2 at 3:30 p.m. CT (4:30 p.m. ET), and the webcast will be available at www.hpe.com/investor/2026Q3Webcast. A replay of the webcast will be available at the same website shortly after the call and will remain available for approximately one year. For add...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Emerging Markets AlphaDEX UCITS ETF 11.08.2026 FEM IE00B8X9NX34 300,002.00 USD 14,885,253.92 49.617  ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--A new survey reveals that U.S. biotechnology companies focused on developing treatments for rare and serious diseases overwhelmingly prefer to conduct first-in-human (FIH) clinical trials in the United States. However, historical obstacles posed by the U.S. Food and Drug Administration (FDA) are prompting them to seek development overseas – in Australia, Europe, and China. The survey of 37 U.S. biotechnology executives was conducted by the Biotech Consortium t...

HANGZHOU, China--(BUSINESS WIRE)--Ant Group today officially upgraded its physician platform, Haodf for Doctor, into AQ for Doctor, an AI-powered workstation designed to support physicians across every stage of clinical practice—from online consultations and patient management to clinical decision support and medical research. The platform is fully integrated with Ant Group's flagship AI health app, AQ, which serves more than 100 million users as of August 2026. Connecting doctors and patients...

AMSTERDAM--(BUSINESS WIRE)--Nebius Group N.V. (NASDAQ: NBIS), the AI cloud company, today announced its unaudited financial results for the three and six months ended June 30, 2026. The Company today also published founder and CEO Arkady Volozh’s quarterly letter to shareholders, available on its investor relations website at https://nebius.com/investor-hub. Management will hold an earnings webcast today at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time / 2:00 p.m. Central European Time). To re...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Eurozone AlphaDEX UCITS ETF 11.08.2026 FEUD IE00BF2FL590  345,463.00 EUR  19,974,035.55   57.818  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Large Cap Core AlphaDEX UCITS ETF 11.08.2026 FEXD.LN IE00BWTNMB87 451,437.00 USD 46,596,015.04 103.217  ...

NEW YORK--(BUSINESS WIRE)--Capstone Holding Corp. (NASDAQ: CAPS), a national, technology-enabled building products distribution platform, today reported financial and operating results for the second quarter of 2026. Revenue grew 67% year over year to $21.5 million, gross profit grew 92% to $6.0 million, and gross margin expanded 357 basis points to 27.9%. Stone Business Adjusted EBITDA was $2.0 million, a 9.4% margin, delivering the positive Stone Business Adjusted EBITDA the Company guided to...

MONTRÉAL--(BUSINESS WIRE)--TOMAGOLD CORPORATION (TSXV: LOT; OTCPK: TOGOF) (“TomaGold” or the “Company”) is pleased to provide shareholders with a corporate update on the multiple exploration work streams currently underway across its Chibougamau property portfolio, anchored by the Berrigan Mine project. Following a productive first half of 2026, the Company has several drilling, geophysical and geochemical activities in progress and expects to generate a steady stream of news flow over the comi...

SEATTLE & CAMBRIDGE, Mass.--(BUSINESS WIRE)--InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of a $77 million Series B financing and the dosing of the first patient in the Phase 1 clinical study of IDP-001, the company’s lead oncology program. Proceeds from the financing will support Phase 1 clinical development and generation of early proof-of-con...